相关实验视频

Updated: Jun 9, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

来自卵巢癌的IL-4可促进免疫疗法抵抗性

Gurkan Mollaoglu¹, Alexander Tepper², Chiara Falcomatà²

¹Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

|October 31, 2024

概括

来自卵巢癌细胞的介质素-4 (IL-4) 产生免疫抑制瘤微环境 (TME),导致免疫疗法耐药性. 向IL-4可能会提高抗PD-1治疗的疗效.

科学领域:

免疫学
癌症学
基因组学

背景情况:

卵巢癌对免疫治疗具有抵抗性,主要是由于巨细胞主导的免疫抑制瘤微环境 (TME).
内异质性进一步使治疗反应复杂化,其发育机制尚不清楚.

研究的目的:

确定卵巢癌免疫力和免疫疗法的关键调节者.
研究瘤-巨细胞沟通在TME形成和推动瘤演变中的作用.

主要方法:

使用空间功能基因组学屏幕 (Perturb-map) 来分析参与瘤巨细胞通信的受体/连接体相互作用.
专注于识别影响卵巢癌免疫逃避和异质性的遗传调节剂.

主要成果:

这项研究确定了互白素-4 (IL-4) 是促进抗PD-1 免疫疗法的关键因素.
卵巢癌细胞被确定为IL-4的主要来源,它通过控制巨细胞来调节免疫抑制TME.
影响TME组成和驱动克隆选择,导致免疫疗法耐药性.

结论:

异质的TME来自局部的细胞因子/化学因子表达,形成富含免疫和免疫排除的区域,促进克隆选择和免疫疗法耐药性.
针对IL-4信号提供了一个有希望的策略,以增强卵巢癌对免疫治疗的反应.

关键词:

美国一个IL-4 乱地图免疫疗法内异质性巨细胞多重成像卵巢癌其他空间CRISPR屏幕空间基因组学瘤免疫学瘤微环境瘤地区第2类免疫

更多相关视频

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...